期刊
JOURNAL OF NEUROSCIENCE
卷 29, 期 33, 页码 10405-10409出版社
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.2288-09.2009
关键词
-
资金
- Deutsche Forschungsgemeinschaft [SFB 596]
- Bundesministerium fur Buildung und Forschung [01GZ0713, 16IN0675 13N9268]
- European Union [FP7-223276]
- Center of Integrated Protein Science Munich
Alzheimer's disease (AD) represents the most common age-related neurodegenerative disorder. It is characterized by the invariant accumulation of the beta-amyloid peptide (A beta), which mediates synapse loss and cognitive impairment in AD. Current therapeutic approaches concentrate on reducing A beta levels and amyloid plaque load via modifying or inhibiting the generation of A beta. Based on in vivo two-photon imaging, we present evidence that side effects on the level of dendritic spines may counteract the beneficial potential of these approaches. Two potent gamma-secretase inhibitors (GSIs), DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester) and LY450139 (hydroxylvaleryl monobenzocaprolactam), were found to reduce the density of dendritic spines in wild-type mice. In mice deficient for the amyloid precursor protein (APP), both GSIs had no effect on dendritic spine density, demonstrating that gamma-secretase inhibition decreases dendritic spine density via APP. Independent of the effects of gamma-secretase inhibition, we observed a twofold higher density of dendritic spines in the cerebral cortex of adult APP-deficient mice. This observation further supports the notion that APP is involved in the modulation of dendritic spine density-shown here for the first time in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据